Goldman Sachs Group set a GBX 4,080 ($53.31) price target on AstraZeneca (LON:AZN) in a research report released on Thursday. The firm currently has a sell rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on the stock. Barclays reiterated an overweight rating on shares of AstraZeneca in a research note on Tuesday, October 9th. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Tuesday, October 16th. Jefferies Financial Group reiterated a hold rating and issued a GBX 5,800 ($75.79) price objective on shares of AstraZeneca in a research note on Friday, October 12th. Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Thursday, August 30th. Finally, Citigroup reiterated a buy rating and issued a GBX 6,200 ($81.01) price objective on shares of AstraZeneca in a research note on Tuesday, September 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of GBX 5,880.82 ($76.84).

LON:AZN opened at GBX 6,172 ($80.65) on Thursday. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.